The neglected tropical disease Buruli ulcer (BU) is an infection of subcutaneous tissue with 26 Mycobacterium ulcerans. There is no effective BU vaccine. Here, we assessed an experimental 27 prime-boost vaccine in a low-dose murine tail infection model. We used the enoyl-reductase (ER) 28 domain of the M. ulcerans mycolactone polyketide synthases electrostatically coupled with a 29 previously described TLR-2 agonist-based lipopeptide adjuvant, R4Pam2Cys. Mice were vaccinated 30 and then challenged via tail inoculation with 14-20 colony forming units (CFU) of an engineered 31 bioluminescent strain of M. ulcerans. Mice receiving either the experimental ER vaccine or 32
Introduction: 48
Buruli ulcer (BU) is a disease primarily of the subcutaneous tissue caused by infection with 49
Mycobacterium ulcerans. BU initially presents as redness of the skin that is often accompanied with 50 oedema and swelling. As the disease progresses, oedema may increase or an open ulcer develop (1, 51 2), the latter is typically characterised by deep undermined edges with a necrotic core comprised of 52 bacteria, dead skin cells and immune cells (3, 4) . Ulcers are predominately found on the extremities 53 of the body such as the upper (27% of cases) and lower limbs (70% of cases) (5). The disease is rarely 54 fatal, but if left untreated extensive destruction of subcutaneous tissue can leave victims with 55 significant deformities and lifelong disabilities (3, (6) (7) (8) (9) . 56 57 BU is likely caused when M. ulcerans is introduced beneath the skin. This can occur if a region of 58 contaminated skin surface is punctured or by insertion of an object contaminated with the bacteria 59 into subcutaneous tissue (e.g. via an insect bite) (10-12). BU-endemic areas include certain regions 60 of West and Sub-Saharan Africa and south eastern Australia (13, 14) . 61 62 M. ulcerans is a slow-growing bacterium, with a doubling time greater than 48 hours (15, 16) making 63 it difficult for early disease diagnosis as symptoms can take between 4-5 months to appear after 64 primary infection (17, 18) . If diagnosed early, however, BU can be treated effectively by combination 65 antibiotic therapy (19) (20) (21) . Unfortunately, in many cases the disease can initially be misdiagnosed 66 as other, more common skin infections. Additionally, a large proportion of BU cases in African 67 countries occur in rural villages and poorer areas with limited or no access to health care, with 68 patients facing disfigurement and permanent disability. Given that diagnoses are delayed and 69 usually occur after a lesion has become relatively advanced and ulceration extensive (22), 70 development of an effective BU vaccine to protect those in highly endemic areas is of paramount 71 importance. 72 73 Currently, the only licensed vaccine against mycobacterial infections approved for human use is the 74 M. bovis-derived Bacille Calmette-Guérin (BCG) vaccine for prevention of tuberculosis. This vaccine 75 is cross-protective against M. ulcerans, but only delays the onset of disease (23) (24) (25) . Several 76 experimental vaccines have been tested against M. ulcerans infection, as summarised in Table 1 . 77
Although different animal models have been utilised to study M. ulcerans infections including 78 guinea pig, primate, pig and armadillo (10, 23, (26) (27) (28) (29) (30) (31) , most studies assessing vaccine efficacy have 79 used mice. Vaccines tested in these murine challenge models have included 80 protein subunit and whole cell vaccines (25, (32) (33) (34) (35) (Table 1 ). Among the various vaccines, BCG 81 expressing M. ulcerans antigens appears to offer the best protective effect against challenge. Hart 82 et al. (36, 37) showed enhanced protection against BU using a recombinant BCG vaccine that 83 expressed M. ulcerans Ag85A or recombinant Ag85B-EsxH fusion protein in a mouse footpad 84 challenge model. Whilst improving the immunogenicity of BCG may be a promising route, there are 85 also some drawbacks; exposure to environmental mycobacteria is believed to decrease the efficacy 86 of the BCG vaccine and administration in areas where people have been BCG-exposed may be 87 problematic (38) . 88 89 M. ulcerans causes disease primarily through the production of a lipid toxin called mycolactone (39) . 90
Mycolactone modulates cell function, in particular secretion of critical cytokines by specifically 91 inhibiting the Sec61 translocon, enabling M. ulcerans to escape host immune defences (40) (41) (42) (43) (44) (45) (46) . The 92 toxin is formed from simple acetate and propionate precursors by three polyketide synthases (PKS) 93 encoded by genes on the plasmid pMUM001 (47, 48) . Within each PKS are enzymatic domains that 94 form the mycolactone molecule. Some of these domains have been found to be immunogenic and 95 in particular immune responses against the enoyl reductase (ER) domain have previously been 96
shown to significantly reduce M. ulcerans bacterial load in the footpad of a murine prime-boost 97 vaccination study (49) . Based on the immunogenic and protective qualities of ER, we have utilised 98 it as a target antigen for a BU subunit vaccine. 99 100 Protein antigens generally require an adjuvant to boost immunogenicity and shape immune 101 responses. A known TLR-2 ligand, R4Pam2Cys, has been previously shown to induce robust antibody 102 responses as well as augmented CD4 + and CD8 + T cell responses, possibly through promoting 103 dendritic cell antigen uptake and trafficking to lymph nodes (50, 51) . Given BU is a disease where 104 the bacteria can be both extracellular and intracellular, the ability of R4Pam2Cys to robustly engage 105 multiple arms of the adaptive immune system may be beneficial for a BU subunit vaccine. 106
107
Previous research has shown that as few as three colony forming units (CFU) of bacteria are required 108 to initiate infection (10), however most animal models challenge with >10 4 CFU (see Table 1 ) (25, 109 32-37, 49, 52-54) . This dose is likely to be far higher than the dose of bacteria that leads to natural 110 infection in humans and other animals (10). Such an unrealistic high dose may overwhelm immune 111 responses and underestimate the true efficacy of potential M. ulcerans vaccines. For these reasons, 112
we have used a low-dose of M. ulcerans in a tail infection challenge model to evaluate an 113 experimental prime-boost subunit vaccine against BU. The experimental subunit vaccine developed 114 here comprised of the M. ulcerans mycolactone ER domain protein formulated with the adjuvant, 115
R4Pam2Cys. Our murine challenge model with physiologically relevant dosing enabled us to more 116 accurately measure vaccine-induced protection and to explore immune correlates of protection 117 against BU. 118 119 120
To evaluate the ability of the vaccine to induce ER-specific antibody responses, mice were 146 vaccinated, and sera obtained after priming and boosting with the subunit vaccine. Our results 147 showed that primary vaccination with ER + R4Pam2Cys resulted in significantly higher levels of ER-148 specific antibody compared to vaccination with unadjuvanted ER antigen (p<0.0001) ( Fig. 1D ). In 149 fact, there was no significant difference in responses between unvaccinated mice and those 150 vaccinated with a single dose of ER alone, R4Pam2Cys only or BCG. Although a second dose of ER 151 alone was able to increase these responses, the titres were still ~100-fold less than levels achieved 152 by boosting mice with ER + R4Pam2Cys (p<0.0001). These results not only indicate that ER-specific 153 antibodies can be generated in mice and that the use of R4Pam2Cys can significantly enhance these 154 responses, but that BCG does not induce cross-reactive antibodies to the ER protein. 155
156

Characterisation of a low-dose M. ulcerans murine tail infection model 157
We have previously described the use of a low-dose tail infection model for studying insect-158 mediated transmission of M. ulcerans (10). We reasoned that because BU patients were likely to be 159 initially infected with a low bacterial inoculum (10, 11, 59) we could use this model to test the 160 protective efficacy of responses induced by the ER + R4Pam2Cys vaccine. This model features the 161 use of a bioluminescent strain of M. ulcerans (10, 60) and its infectious characteristics are 162 summarised in Fig. 2 . Compared to an uninfected tail (Fig 2A and C) , sub-cutaneous infection of a 163 tail results in the appearance of a visible ulcer ( Fig 2B) exhibiting the highest levels of 164 bioluminescence concentrated around the centre of the lesion (Fig 2D) , i.e. where swelling appears 165 to be the greatest, and beginning to diminish around the periphery reflecting a positive correlation 166 between bacterial burden and light emission (61). Histological cross-sections revealed that while 167 tissue integrity of an uninfected tail appears defined and intact ( Fig. 2E & F ), dramatic differences 168 are observed in the infected tail, typified by loss of muscle, vasculature and epidermis structure and 169 disruptions to surrounding connective tissue (Fig. 2G & H) . Further examination of this tissue 170 showed the presence of acid-fast bacilli as well as an infiltration of polymorphonuclear cells (PMNs) 171 ( Fig. 2I ). Despite evidence of bacteria engulfment by these cells (Fig. 2J) , it would appear that this 172 response was insufficient for controlling the infection and preventing disease progression. 173 174
Monitoring vaccine efficacy using bioluminescent M. ulcerans and in vivo imaging system (IVIS) 175
We have previously established a correlation between M. ulcerans bioluminescence and bacterial 176 burden (61). Here, we set a threshold of ≥ 5x10 5 photons/second (equivalent to 2.8x10 5 CFU) as a 177 measure of ineffective disease control, i.e. appearance of disease. Mice were vaccinated 178 subcutaneously and then challenged with an estimated 17 CFU (range 14-20 CFU) of bioluminescent 179 M. ulcerans via intradermal tail inoculation. Animals were monitored weekly for changes in 180 bioluminescence using IVIS for up to 24 weeks. Fig. 3A shows an example of the progression of 181 bioluminescence (and therefore disease) in an unvaccinated mouse, up to week 16 whereupon the 182 clinical endpoint of the experiment was reached. Bioluminescence for all mice was recorded across 183 the experimental period. Plots for the different treatment groups show the progression in 184 bioluminescence over time (Fig3B-F). Mice from the ER alone, R4Pam2Cys alone and unvaccinated 185 treatment groups displayed the first detectable bioluminescence at week 7. There also appeared to 186 be threshold in bioluminescence, whereby animals expressing ≥5x10 5 photons/second from tail 187 lesions became less able to control the infection and progressed to the clinical endpoint ( Fig. 3B ). 188
The immune response data for all mice is provided ( Supplementary Table S1 ). Using these data, 189 failure-to-protect was defined as tail bioluminescence equal to or greater than 5x10 5 190 photons/second at or before week 24 (end of experiment). Therefore, mice were defined as 191 'protected' if bioluminescence was less than 5x10 5 photons/second at week 24. 192
193
Vaccination with ER + R4Pam2Cys offers similar protection to M. bovis BCG vaccine 194
Survival analysis was conducted to assess vaccine efficacy by measuring the time from infection until 195 tail bioluminescence at the threshold of 5x10 5 photons/second was reached. Mice that reached this 196 threshold were defined as 'not protected'. Significantly less ER + R4Pam2Cys vaccinated mice (4/10 197 animals) developed disease compared to unvaccinated mice (9/10 animals), indicating ER + 198 R4Pam2Cys provided some level of protection against disease progression compared to no 199 vaccination ( Fig. 3B , E & G) (p<0.01). Mice vaccinated with BCG were best protected with only 1 200 animal exceeding the bioluminescence threshold (Fig. 3F & G) . Although this number of mice was 201 reduced compared to the ER + R4Pam2Cys vaccinated animals, the difference was not significant 202 ( Fig. 3G ). However, the bacterial burden (as indicated by mean photon counts/sec at the clinical 203 endpoint) in BCG vaccinated mice was lower than animals that received the ER + R4Pam2Cys vaccine 204 (means: 6x10 5 [n=2, range 3.5 -8.6x10 5 ] versus 3.3x10 7 [n=3, range 2.4 -4.1x10 7 ] photons/sec 205 respectively) suggesting the protective superiority of BCG. There was also no significant difference 206 between the protective efficacy of vaccination with ER alone compared with ER + R4Pam2Cys, 207 although mice vaccinated with the latter exhibited delayed disease progression (onset at weeks 16-208 24) compared to ER vaccinated mice (onset at weeks 8-16) indicating that formulation of the 209 antigen with the R4Pam2Cys adjuvant improved immunity ( Fig. 3D , E). 210 211
Measuring immune parameters following vaccination and challenge 212
At the experimental end-point, sera, spleens and draining lymph nodes (DLN) from all animals were 213 collected and several parameters were further analysed; ER-specific antibodies, CD4 + and CD8 + T 214 cells and a panel of 11 murine Th1, Th2 and Th17 cytokines. After M. ulcerans challenge, mice 215 vaccinated with ER alone or ER + R4Pam2Cys were found to exhibit significantly more ER-specific 216 antibodies than the other treatment groups ( Fig 4A) despite not being fully protected. This indicates 217 that, even though the ER protein is highly immunogenic, anti-ER antibodies do not appear to play a 218 major role in controlling infection. 219
We next investigated if there were any differences in the ability of T cells harvested from the spleens 220 of vaccinated mice to produce cytokines following stimulation with recombinant ER protein 221 ( Supplementary Table S1 ). Our results showed that the numbers of IFN-γ producing CD4 + T cells 222 across all vaccine groups did not differ, and in some cases, were higher in unvaccinated mice 223 compared to those vaccinated with ER + R4Pam2Cys vaccine group ( Fig 4B) indicating that there was 224 no clear correlation between the frequencies of these cells and protection. Similarly, there also did 225 not appear to be any correlation between TNF-α + CD4 + T cells, IFN-γ + CD8 + T cells or TNF-α + CD8 + T 226 cells and protection ( Supplementary Table S1 ). 227
228
Comparing levels of cytokine production between vaccine groups also did not clearly identify any 229 cytokines that correlated with protection (see Supplementary Table S1 ). For example, higher levels 230 of TNF-α were present in the spleens of unvaccinated mice than BCG vaccinated mice ( Fig 4C) and 231 even though BCG vaccination resulted in significantly more IFN-γ in draining lymph nodes compared 232 to unvaccinated mice, this was not observed for ER + R4Pam2Cys vaccinated mice ( Fig 4D) . 233
234
We therefore based our analysis on comparisons between diseased or protected mice irrespective 235 of the vaccines they received ( Fig. 4E,F ). Herein, we identified significant increases of IL-2, IL-6, IL-236 10 IL-17A, IFN-γ, MIP-1b, TNF-α in the lymph nodes of protected mice ( Fig. 4F ) and significant 237 increases of IFN-γ, IL-6, and TNF-α in the spleens of diseased mice (Fig. 4E ). While these data 238 implicate these cytokines as correlates of protection and disease, it did not rank the importance of 239 each cytokine towards either outcome. 240 241
Identifying immune responses that predict vaccination outcome 242
To identify the immune parameters (features) that associate with the response variable 'vaccine 243 protection' (here measured as time to reach our bioluminescence detection threshold) independent 244 of the vaccine used, we conducted a univariate regression analysis using the Cox proportional 245 hazards model. We used this model as it accounts for the fact that a subset of mice (observations) 246 was right-censored, as vaccination outcomes were not measured after 24 weeks post challenge. For 247 each of the 28 immunological features, their association with the response variable (time-to-248 bioluminescence measured in weeks) was ranked using concordance index (CI) scores. The CI is 249 analogous to the area under the ROC curve, with a CI value of 0.5 indicating a random correlation 250 and 1 indicating a perfect, positive correlation (62). The CI for each univariate regression analysis 251 was used to rank the strength of association for each of the 28 features against the response 252 variable. Using a CI cut-off of 0.70, the top six features were identified as well as the direction of 253 their association with prevention of development of bioluminescence (Table 2 ). Low levels of IFN-γ 254 and high levels of IL-2 produced in mouse splenocytes were the top two immune parameter features 255 influencing this model, reflected in the individual correlation between their respective titres and 256 time-to-bioluminescence ( Fig. 5A, B) . 257 258 Next, using these top six features, we performed unsupervised machine learning to reveal any 259 structure without the influence of labels, such as arbitrarily imposed bioluminescence thresholds. 260
Here, the data separated into two main clusters. K-means clustering was then applied to assign mice 261 (observations) to the two cluster groups. Inspection of the resulting cluster membership with 262 respect to time to bioluminescence showed a separation of the mice either side of 17 weeks post 263 M. ulcerans challenge ( Fig. 5C ). 264
265
Given that the clusters identified through unsupervised learning closely resembled a temporal 266 breakpoint at 17 weeks, we further investigated this binary divide in the data. We used multivariate 267 logistic regression and developed a low-error classifier that could generalize to unseen data, using 268 the underlying structure apparent in the immunological data. We then tested the classifier through 269 extensive cross-validation. Observations (mice) with bioluminescence above threshold between 270 weeks 8-17 were assigned a '0' and '1' for those with bioluminescence detected in weeks 18-24 or 271 no detection throughout the experiment period. The model included the top six features (Table 2) (Table 2) . This association of BU and the production of inflammatory cytokines (IL-6, IFN-γ and TNF) 282 as possible markers of infection, indicated that we could also identify correlates of immune 283 protection against BU. 284 285
Assessment of vaccine-specific immune responses 286
To dissect the immune responses associated with ER + R4Pam2Cys vaccination versus BCG and the 287 different controls we noted the differences in the percentage of observations (mice) belonging to 288 specific treatment groups between the two clusters observed above (Fig. 5C ) separated by week 17. 289
This summary was reflective of the survival analysis and showed that unvaccinated mice and those 290 that received the adjuvant or ER alone were predominantly in the weeks 8-17 cluster, while ER + 291
R4Pam2Cys and BCG-vaccinated mice were predominantly in the weeks 18-24 cluster (Fig. 5E ). In 292 order to obtain the individual immune profile of the different treatment groups, group-specific 293 univariate logistic regression analyses were undertaken. Here, the response variable was coded as 294 a '1' for membership in a particular group and '0' for membership in all other groups. Analyses were 295 conducted for each of the five treatment groups and the model coefficient weights were used to 296 determine both the strength and direction of association of each feature with that of each 297 treatment group. The resulting p-values from the model coefficients were used to assess 298 significance of the associations (Fig. 5F , Supplementary Table S2 ). The combination of the ER antigen 299 and R4Pam2Cys together were important for inducing protective responses that associated with 300 local production of IL-4, IL-2, IL-17A in the DLN, in addition to ER-specific antibody responses. 301
Neither ER antigen or R4Pam2Cys alone induced this profile and protection using the former was 302 only linked to ER-but not M. ulcerans-specific antibody responses (post-challenge timepoints). In 303 comparison, BCG vaccination-mediated protection was associated with a greater breadth of 304 localised cytokines responses than ER + R4Pam2Cys, with higher IL-6, TNF-α and MIP-1β in the DLN. 305
Of note, evidence of systemic inflammation, such as IL-17A and IFN-γ in the spleen was associated 306 with poorer BCG performance. 307 308 Discussion 309
In this study, we investigated various immune parameters induced by the use of BCG and an 310 experimental subunit vaccine against BU and sought to identify immune correlates associated with 311 protection in a mouse tail infection model. Studies have shown that the tail is a suitable location for 312 infection as BU predominantly affects extremities (11, 52, 63) and in combination with the use of 313 bioluminescent M. ulcerans, offers several advantages over footpad, hock or ear infections used in 314 most BU vaccine studies (as shown in Table 1 and (64)). Tail infections are less likely to affect mouse 315 mobility, or cause rapid tissue loss and may also prevent added trauma, inflammation or secondary 316 infections at the challenge site (65). A key feature of this model also allows the use of a significantly 317 lower bacterial challenge dose compared to other studies (approximately 14-20 CFU compared to 318 10 4 -10 6 CFU) (25, 32-37, 49, 52-54) (Table 1 ) and enables measuring bacterial growth in the same 319 animal over time. This lower dose is likely to be more physiologically relevant, in terms of reflecting 320 the bacterial inoculum that occurs during M. ulcerans transmission to humans (10, 11, 59) . Sporadic 321 healing of BU disease was also seen in this model, an observation that has been noted in humans 322 and other animals (29, (66) (67) (68) . 323
324
Vaccination with the ER + R4Pam2Cys formulation resulted in protection of 60% of mice from BU 325 challenge. Although more of these vaccinated mice reached our defined disease outcome after 24 326 weeks compared to BCG-vaccinated mice, the difference was not statistically significant. There was 327 also no significant difference in the number of mice displaying any bioluminescence between each 328 group. The fact that ER + R4Pam2Cys was significantly more protective than vaccination with 329
R4Pam2Cys alone indicates any non-antigen specific triggering of innate immune responses by this 330 adjuvant (69, 70) (71) was not sufficient for conferring long-lasting protection and the inclusion of 331 the ER protein was necessary to achieve any protective effects. This was further evident by 332 vaccinating with ER alone. Despite not seeing any clear significant differences in the clinical 333 outcomes at the end of the trial when compared to ER + R4Pam2Cys vaccination, the inclusion of 334 R4Pam2Cys delayed disease onset by ~8 weeks and correlated with the induction of significantly 335 more ER-specific antibodies after a primary and booster vaccination. 336
337
The presence of these antibodies was nonetheless insufficient to provide total protection against 338 M. ulcerans challenge. This is perhaps not unexpected given that other studies have also reported 339 little correlation between strong BU antibodies and protection, in mice (34) or sera of BU patients 340 (57, 72) . To identify other immune correlates associated with the protective effects observed in our 341 study, a Cox proportional hazards regression model was utilized. Here, the univariate analyses 342 allowed us to identify the top six features that most strongly associated with differences in time to 343 detection of bioluminescence. These models assume normalized data, and although we cannot infer 344 how much an increase or decrease in units could affect the clinical outcome, we are able to rank 345 each factor based on its contribution to either disease or protection. This model also considers the 346 effect of each factor in delaying the onset of disease rather than just modelling through a binary 347 'protected' or 'diseased' outcome. Similar regression modelling has been described to predict 348 outcomes for tuberculosis patients after treatment, effect of hospital-acquired Clostridium difficile 349 on hospital stay and survival of Staphylococcus aureus in milk (73-75). The model assumes that 350 eventually all mice will succumb to disease and due to the constraints in our data, it cannot 351 determine threshold levels of cytokines that will predict disease outcomes. 352
353
The cytokines most associated with protection in BCG mice were different to those identified in 354 mice vaccinated with ER+R4Pam2Cys, which is not surprising given that BCG is a multi-antigen live-355 attenuated vaccine and thus likely to utilise both common and distinct protective responses and 356 mechanisms to those induced by our vaccine candidate. 357
358
Through multivariate logistic regression modelling we identified the presence of IL-2 in the spleen 359 and lymph nodes as markers that were most strongly associated with protection. Although there 360 are no studies that directly link IL-2 with protection against M. ulcerans, it plays a key role in the 361 differentiation, proliferation and maintenance of T cell responses (76). Therefore, it is perhaps not 362 surprising that its role in this murine model is likely to be important for the induction of protective 363 adaptive immunity against M. ulcerans. 364 365 However, our results did not show any correlation between levels of cytokine producing CD4 + and 366 CD8 + T cells and protection in vaccinated groups despite studies that have shown them to play a 367 role in BU control (77, 78) . In particular, M. ulcerans-specific CD4 + T cells have been found to migrate 368 to the site of infection from draining lymph nodes early in infection but are depleted as the infection 369 persists (77), an effect that could be attributed to the ability of the M. ulcerans exotoxin 370 mycolactone to impair T cell and macrophage function (41, 44, 78) . 371
372
In addition, we also identified the presence of systemic IL-6, TNF-α and IFN-γ (in the spleen) to be 373 strongly associated with disease. IL-6 is a pro-inflammatory cytokine produced by many cell types 374 in response to pathogens and is linked to the production of TNF-α, both of which can be detected 375 in BU lesions and serum of BU patients (78, 79) (80). TNF-α in particular, plays a key role in 376 inflammatory cell recruitment and in conjunction with IFN-g, increases the phagocytic ability of 377 macrophages to enhance killing of mycobacteria (81, 82). However many studies have shown that 378 mycolactone suppresses TNF-α production by T cells and especially macrophages (83, 84), 379 decreasing their ability to control BU infection (85). 380 381 IFN-g itself has also been shown to be important for controlling M. ulcerans infection as IFN-g 382 deficient mice cannot prevent the onset of disease (86). It is also detected at high levels in patients 383 with both developed ulcers and early lesions (87) and healed ulcers (88) where it is believed to 384 mediate macrophage function (89) and drive iNOS expression to facilitate bacterial killing (90). 385
Altogether, the fact that these cytokines are elevated at a systemic level in the diseased animals in 386 our study but not in lymph nodes draining from the tail suggests that their activity is being 387 dampened at the site of infection. These effects do not appear to be present in protected animals 388 where increased levels of cytokines are detected in the draining lymph node and not the spleen. In 389 fact, the localised, but not systemic presence, of these and other cytokines including IL17A, MIP1b 390 and IL10 are strongly associated with protection. 391 392 Although most of the immunosuppression during BU infection can be attributed to mycolactone, 393 chronic inflammation can also be key driver as noted by the increased splenic cytokine levels. Many 394 cell types have been implicated as the cause of immunosuppression in cancers, chronic viral 395 infections (such as HCV, HIV, HBV) and even M. tuberculosis infection. These include myeloid-396 derived suppressor cells (MDSCs) (91) regulatory T cells (Treg) (92) and T helper 17 (Th17) (93), which 397
can suppress effector T cell function and inhibit NK and dendritic cell activity through direct cell-to-398 cell interactions or the production of immunosuppressive cytokines. MDSCs in particular can be 399 recruited by IFN-γ (94) and IL-6 (95), both of which are found in higher levels in our unprotected 400 mice. On the other hand, while Th17 cells are crucial for the control of infection, especially 401 extracellular bacterial and fungal infections, elevated frequencies can lead to tissue inflammation 402 alongside matrix destruction, autoimmunity and vascular activation (96). The observation that 403 higher systemic IL-17A correlates with the lack of protection suggests that these cells play a role in 404 determining BU disease outcomes. 405
406
Tissue changes due to chronic infection could also play a compounding effect on the severity of BU 407 disease outcomes. Our histological analysis of BU-infected tail tissue showed a loss of muscle and 408 epidermis, changes in connective tissue and loss of vasculature which may explain why lymphocytes 409 and other immune cells are unable to access the sites of greatest infection and tissue damage. BU 410 tissue necrosis can also extend some distance from the site of bacterial colonisation, an observation 411 that led to the identification of mycolactone as the cause of coagulative necrosis (39, 97, 98) . 412 Mycolactone has been well described as causing cell death to skin-resident cells such as fibroblasts, 413 adipocytes, keratinocytes and endothelial cells (39, 99, 100). Primary human dermal microvascular 414 endothelial cells are especially sensitive to mycolactone and after exposure lose their ability to 415 activate a key anticoagulant protein (protein C) after exposure, causing a reduction in intravascular 416 fluidity and preventing immune cell infiltration to the infection site (99). Thus, the combination of 417 immunosuppressive immune host responses and tissue destruction, in conjunction with 418 mycolactone at the site of infection, may increase the risk for poorer disease outcomes for those 419 chronically infected with BU. 420 421 Although we have identified several factors associated with disease and protection, our results 422 provide impetus to further expand these profiles and establish their importance. For example, 423 changes in cytokines levels before challenge and throughout the infection phase could be monitored 424 and integrated into models, as well as analysing frequencies of various other innate-and adaptive-425 immune cell populations and identifying those that produce cytokines of interest. In evaluating and 426 demonstrating that a subunit vaccine can protect against BU in our mouse challenge model, albeit 427 not as efficacious as BCG, our results showed that protection can be mediated through different 428 immune mechanisms. Disease progression was also commonly linked to the presence of pro-429 inflammatory cytokines in the spleen and not the lymph node. These profiles indicate that localised 430
and not systemic responses are more important for conferring protection and also provide a 431 template that could guide the design and development of novel vaccination strategies against BU. 432 433 Finally, we conclude that the mycolactone biosynthesis pathway constitutes a viable vaccine target 434 to protect against M. ulcerans. As M. ulcerans is slow-growing and requires its highly conserved 435 mycolactone PKS for virulence, the development of resistance is unlikely. As such, approaches based 436 on the use of multiple PKS enzymatic domains may prove even more efficacious. Moreover, studies 437 that have introduced M. ulcerans and M. marinum-specific proteins into BCG have been shown to 438 increase its protective effect. Collectively, this demonstrates the additive power of using a broader 439 suite of antigens and the potential for a viable vaccine against BU. 440 441
Methods: 442
Strains and culture conditions. 443
Escherichia coli ClearColi©BL21 (DE3) containing the plasmid, pJexpress-ER (strain TPS847) was 444 grown at 37°C in Luria-Bertani (LB) broth (Difco, Becton Dickinson, MD, USA) supplemented with 445 100 µg/ml ampicillin (Sigma-Aldrich, USA) to express the enoyl reductase (ER) protein (57). Log-446 phase bioluminescent Mycobacterium ulcerans (strain JKD8049 containing integrated plasmid 447 pMV306 hsp:luxG13) (10, 60) was grown at 30°C in 7H9 broth or 7H10 agar (Middlebrook, Becton 448 Dickinson, MD, USA) supplemented with oleic acid, albumin, dextrose and catalase growth 449 supplement (OADC) (Middlebrook, Becton Dickinson, MD, USA), 0.5% glycerol (v/v) and 25 µg/ml 450 kanamycin (Sigma-Aldrich, USA). M. bovis BCG (strain 'Danish 1331') used for vaccinations was 451 grown at 37°C in 7H9 broth or 7H10 agar supplemented with OADC. Mycobacterial colony counts 452 from cultures or tissue specimens were performed using spot plating as previously described (10). 453
All culture extracts were screened by LC-MS for the presence of mycolactones as previously 454 described to ensure bacteria used in transmission experiments remained fully virulent (101). 455 456
Recombinant protein expression 457
Overnight culture of E. coli TPS847 was diluted to OD600 = 0.05 in LB broth. The culture was incubated 458 at 37°C with shaking at 200 rpm until OD600 = 0.6-0.7, followed by the addition of 1 mM IPTG 459 (Isopropyl b-D-1-thiogalactopyr-anoside) to induce protein expression for a further four hours. Cells 460 were then resuspended in wash buffer (8 M urea, 150 mM sodium chloride, 10% glycerol) and 461 sonicated at amplitude 60 (QSonica Ultrasonic Liquid Processor S-4000, Misonix) until the solution 462 turned clear. The lysate was filtered with a 0.22 µM filter (Millipore) to remove cellular debris and 463 protein was column-purified using anti-histidine resin (ClonTech). The resin was washed with wash 464 buffer which was gradually replaced with tris buffer (20 mM Tris-HCl, 150 mM sodium chloride, 10% 465 glycerol) over ten washes followed by two washes with tris buffer containing 20 mM imidazole. 466
Protein was eluted in tris buffer containing 200 mM imidazole and dialysed in phosphate buffered 467 saline (PBS) before concentration using a microcon column (Millipore). Proteins were tested for 468 endotoxin contamination using Pierce TM limulus amoebocyte lysate assay (Thermo Scientific TM ) and 469 relative size was confirmed by sodium dodecyl sulphate polyacrylamide gel electrophoresis. The association between protein and R4Pam2Cys was measured using dynamic light scattering (DLS) 496 by mixing 5 µg of protein with increasing amounts of lipopeptide in 50 µl PBS. The size distribution 497 of particles in solution (presented as hydrodynamic radius) were measured in 4µl of cyclin olefin co-498 polymer cuvettes using a DynaPro NanoStar DLS instrument (Wyatt Technology, CA, USA) equipped 499 with 658nm laser with a scattering angle of 90°. Measurements were acquired in triplicate with each 500 measurement consisting of 30 readings at 5 second intervals at 25°C. Data was analysed using 501 Dynamics software (v7. 1.7.16) . 502 503
Vaccination of animals 504
The synthesis and purification of the branched cationic lipopeptide, R4Pam2Cys, was performed as 505 previously described (103, 104) . Each vaccine dose contained 25 µg protein formulated in PBS with 506
R4Pam2Cys at a 1:5 molar ratio of protein to lipopeptide in a final volume of 100 µl. Live-attenuated 507 M. bovis BCG strain 'Danish 1331' was grown to log phase and stored at -80°C in 20% glycerol until 508 used. Bacteria were washed with PBS and resuspended in 200ul, before administration at 4.7 x 10 5 509 bacteria per dose. All vaccines and control formulations were sonicated for 5 minutes in a waterbath 510 sonicator before being administered. 511 512 Female 6-week old BALB/c mice were sourced from ARC (Canning Vale, Australia) and housed in 513 individual ventilated cages. Food and water were given ad libitum. Experiments were approved by 514
The University of Melbourne Animal Ethics Committee (Approval identification number: 1613870). 515
For vaccination using R4Pam2Cys, animals were inoculated subcutaneously at the base of tail (100µl 516 per dose at 50 µl per flank) and boosted 21 days later with the same formulations. Mice vaccinated 517 with M. bovis BCG were given one dose subcutaneously in a similar manner (200 µl per dose at 100µl 518 per flank). There were 10 mice in each vaccination group. 519 520 M. ulcerans challenge 521
Mice were challenged with bioluminescent M. ulcerans on day 35 as described previously (10). 522
Briefly, tails of isoflurane anaesthetised mice were dipped in 7H9 culture containing log-phase 523 bioluminescent M. ulcerans bacteria (concentration 1.27 x 10 6 CFU/mL (range: 1.07x10 6 -1.46 x10 6 524 CFU). Contaminated tails were then pierced once subcutaneously with a sterile 25-G needle. The 525 infectious dose was calculated to be 17 CFU (range: 14-20) using methods previously described (10). 526
Mice were allowed to recover and monitored for up to 24 weeks after infection and sacrificed when 527 tail ulceration was observed wherein spleens, lymph nodes and sera were harvested for 528 immunological analysis. 529
530
IVIS imaging 531
Infected mice were imaged weekly from 6-weeks post-infection to detect the emission of 532 Serum antibody titres were measured by enzyme linked immunosorbent assay (ELISA) (105) using 539 plates (Nunc, Thermo Scientific) that were previously coated with antigen overnight, either purified 540 recombinant ER protein or heat-killed whole cell M. ulcerans lysate. The presence of bound 541 antibodies were detected by incubating serum-exposed wells with horse radish peroxidase 542 conjugated rabbit anti-mouse IgG (Dako, Glostrup, Denmark) for 2 hours followed by the addition 543 of the enzyme substrate (0.2mM ABTS in 50mM citric acid containing 0.004% hydrogen peroxide 544 and left to develop for 10-15 minutes before the addition of 50nM sodium fluoride to stop the 545 reaction. Plates were read at dual wavelengths of 505 and 595 nm on plate reader (LabSystems 546
Multiskan Multisoft microplate reader) and antibody titres expressed as the reciprocal of the 547 highest dilution of serum required to achieve an optical density of 0.2. 548 549
Intracellular cytokine staining 550
Single cell suspensions were derived from the spleen and draining lymph nodes and resuspended in 551 RP10 media (RPMI 1640 (Sigma) supplemented with 10% foetal bovine serum (Gibco, ThermoFisher 552 Scientific, Waltham, MA USA), 2mM L-glutamine, 1mM sodium pyruvate, 55 µM 2-553 mercaptoethanol, 12 µg gentamycin, 100 U/ml penicillin and 100 µg/ml streptomycin). Spleen and 554 lymph node-derived cells were cultured in 96-well plates (CoStar, Corning, USA) at 1 x10 7 cells/per 555 well and 1 x10 5 cells/well, respectively 200 µl of RP10 containing 10 U/ml Mannheim, 556 Germany), 1µg/ml plate-bound anti-CD28 (BD Pharmingen, Becton Dickinson, Clone 37.51) and 20 557 µg/ml ER protein for 12 hours at 37°C in 5% CO2. Golgiplug (1µg/ml) (Becton Dickinson) was added 558 for the last 4 hours of incubation. Cells were then stained with 7AAD-Live/Dead stain dye (Biolegend, 559 CA, USA), BV510-anti-B220 (BD Horizon, Becton Dickinson, Clone RA3-6B2), BV605-antiCD4 560 (Biolegend, Clone RM4-5), APC-Cy7-anti-TCRb (BD Pharmingen, Clone H57-597) and PE-Cy7-anti-561 CD8 (BD Pharmingen, Clone 53-6.7) anti-mouse monoclonal antibodies at 4°C in the dark. 562 Neelsen-or H&E-stained prior to microscope imaging. Images of tail segments were captured using 581 a light microscope (Olympus BX53 Light microscope, Olympus-Life Science). 582 583
Statistical analysis 584
GraphPad Prism software (GraphPad Software v7, CA, USA) was used to perform statistical analyses 585 on the antibody titre, time to luminescence, T cell numbers and cytokine titre data. Antibody titres 586 were analysed using one-way ANOVA with Tukey's correction for multiple comparisons. The time to 587 bioluminescence data was displayed as a Kaplan-Meier plot and differences determined using a Log-588
Rank (Mantel-Cox) test. Mann-Whitney tests were performed to compare cytokine titres between 589 protected and diseased mice and for comparisons between vaccination groups. All tests were 590 conducted at the 5% significance level. 591 592
Statistical modelling 593
Twenty-eight data features (i.e. the immune parameters measured in each mouse, refer to Table  594 S1) were transformed using the R package bestNormalize (106). Transformed features were then 595 normalised (between 0 and 1 for each feature) using the MinMaxScaler function of Scikit-learn 596 (107). As many of the vaccination outcome observations (time-to-bioluminescence) were right-597 censored, we employed the Cox proportional hazards regression analysis using the Scikit-survival 598 module of Scikit-learn in Python (108). Here, univariate analyses were run for each of the 28 features 599 using the continuous response variable of time-to-bioluminescence. The standard metric for 600 assessing the predictive performance of a survival model is the concordance index (CI) (62, 109, 601 110). A CI >0.7 was used to identify the top six features of this model. Unsupervised learning and 602 data dimensionality reduction is an ideal way to identify structure in continuous data without the 603 influence of labels. The method of t-Distributed Stochastic Neighbor Embedding (t-SNE) is a 604 dimensionality reduction technique that retains both the global structure and local layout of the 605 high-dimensional data through exchanging the Euclidean distances between all pair of data points 606 into heavy-tailed conditional probabilities (111). This method is advantageous over conventional 607 principal component analysis (PCA), as it does not rely on a linear assumption and can capture 608 nonlinear relationships (111). We explored the data, independent of labels, by reducing the top six 609 features obtained from the Cox proportional hazards regression analysis to a two-dimensional space 610 using the t-SNE package in Scikit-learn (107) . The two clusters detected through visual inspection 611 were objectively defined, with observations assigned to two groups using K-means clustering, as 612 implemented in Scikit-learn (107). A multivariate logistic regression classifier was then built using 613 the top six features, with the two clusters identified by t-SNE as the response variables. To reduce 614 the possibility of over-fitting, the model was validated through 1,000 random train-test splits, in 615 which 90% of the observations made up each training set. These models were built using the logistic 616 regression classifier as implemented in Scikit-learn (107) and Receiver-Operator-Characteristic 617 curves were used to evaluate model performance (112) . In order to assess the immune features 618 that were associated with different vaccination groups, a univariate logistic regression analysis was 619 then conducted for each group using R (112). The estimated model coefficients were used to assess 620 the direction and strength of the association, and the corresponding p-value used to determine 621 statistical significance at the 5% significance level. 622 
